Compare KB Financial Group, Inc. (KB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Mesoblast Limited — how do they compare? KB Financial Group, Inc. trades at $120.14 (market cap $38.56B), while Mesoblast Limited trades at $16.32 (market cap $2.17B). The key difference: KB Financial Group, Inc. is far larger — about 17.8× Mesoblast Limited's market cap, and KB Financial Group, Inc. pays a 2.72% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| KB | MESO | |
|---|---|---|
Market Cap | $38.56B | $2.17B |
Sector | Financials | Technology |
52-Week High | $123.25 | $20.96 |
52-Week Low | $77.50 | $12.88 |
Dividend Yield | 2.72% | — |
Enterprise Value | — | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $115.23, down 3.47% today, but maintains a bullish technical outlook with strong moving average signals. The company shows solid fundamental performance with a 27.82% net income margin and consistent earnings beats in recent quarters. Revenue growth has been steady, reaching $21.23T in 2025, while analyst sentiment is mixed with a 33.33% buy rating amid broader hold consensus. Recent news highlights diversification into non-banking segments, which now contribute 43% of earnings.
The stock presents a balanced outlook with upside from earnings growth and diversification efforts, but faces risks from volatile cash flows and macroeconomic pressures. Investors should weigh the attractive valuation metrics against execution risks in non-banking expansion. The current price near recent highs suggests cautious optimism is warranted.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
